Orin
MONYSE·Tobacco

Altria Group, Inc. MO

Market cap $116.5BP/E 14.5× trailingGross margin 71.0%Reports Thu 29 Oct, before the open
$69.77
+0.81 (+1.18%)live 09:35 ET
52-wk $54.70 – $77.06
Watch
Orin's take
0.62conviction · moderate
Refreshed 17 Aug · take v6. A new filing or a print queues the next refresh.

Altria trades at a compelling 53% P/E discount to consumer-staples peers (13.9x vs. 29.8x median) and generates robust $9.1B free cash flow, but the 2025 net income collapse to $6.9B (EPS $4.11 vs. $6.54 in 2024) despite rising operating income to $12.0B signals material below-the-line charges that remain unexplained. Secular revenue erosion from $21.1B (2021) to $20.1B (2025), negative book equity of -$3.5B, and $25.7B in total debt compound the uncertainty, while the stock sits exactly at its 200-day MA ($65.67) with RSI at 37 and a collapsed smart money score (0.124 to 0.014 over twelve months).

The dividend story and valuation discount are real, but weak institutional flows, insider net selling, and deteriorating bottom-line quality argue for patience until the next earnings print clarifies the net income gap.

What could go wrong

  • Below-line earnings erosion. 2025 net income fell 39% to $6.9B from $11.3B in 2024 despite operating income rising to $12.0B, pointing to large non-operating charges (interest, tax, or one-time items) that could persist.
  • Secular revenue decline. Revenue has contracted every year from $21.1B in 2021 to $20.1B in 2025, and cigarette volume declines plus oral tobacco weakness may accelerate the trend.
  • Leverage and negative equity. Total debt of $25.7B against negative stockholders' equity of -$3.5B limits financial flexibility and raises balance-sheet risk if cash generation slows.
  • Institutional outflows. Smart money score collapsed from 0.124 to 0.014 over the past year, and recent 13F filings show institutions like Banco Santander cutting stakes by 97.5%.

What would change my mind

Earnings clarity. Next quarterly report reconciles the operating-to-net-income gap with non-recurring charges and confirms FCF trajectory above $9B annualizedbullish
Technical breakdown. Stock closes decisively below the 200-day MA ($65.67) on volume, confirming trend reversalbearish
Dividend coverage strain. Free cash flow falls below $8B annualized or debt-to-FCF leverage deteriorates meaningfullybearish

Where this comes from: peer_relative composite · FMP fundamentals FY2025 vs FY2024 · FMP fundamentals FY2025 vs FY2024 · FMP fundamentals FY2025. Orin's read on MO; not advice.

Twelve months actual closes to 2026-09-23 · actual filings

Sept 25Nov 25Jan 26Mar 26May 26Jul 26

50-day average 200-day average · volume below

Largest holders · 13F Q2 2026

Money flow
FilerPositionOf fund
Vanguard Capital Management$7.8B0.2% of fund
State Street$5.1B0.2% of fund
Charles Schwab Investment Management$4.3B0.6% of fund
Capital Research Global Investors$4.2B0.6% of fund
Geode Capital Management$3.4B0.2% of fund
Vanguard Portfolio Management$2.4B0.1% of fund

137 filers · quarter ended Q2 2026 · positions, not flows

Insiders, last 24 months: 53 Form 4 filings, net −$15.5M. Of the 50 on hand, 1 was an open-market purchase and 3 sales— the rest are grants, option exercises and tax withholding.

Ask Orin about MO

its filings · its transcripts · its numbers

Orin answers questions about MO from its filings, transcripts and numbers — with the source behind every claim. Your own desk starts with 3 free days, card required.

Start 3 free days

Where it trades

vs its own 5y · Consumer Defensive
MetricNowOwn medianSector
P/E14.5×13.9×38.3×
EV/EBITDA11.7×10.9×
P/S5.27×4.14×

Its P/E sits 80th percentile of its own last 5 years (−0.15σ from its own mean).

What the price assumes

1.5%

free-cash-flow growth every year for 10 years, discounted at 10%, is what today’s price implies — starting from $9.1B of trailing free cash flow. It is an assumption the market is making, not a forecast Orin is making.

What Wall Street published

26 firms · 2026-09-23
Consensus target

$71

$58$79 · +2% against today's price

How they rate it
  • 16 buy or overweight
  • 9 hold
  • 1 underweight or sell

The analysts’ consensus and their own ratings, not Orin’s. A target is a twelve-month opinion published by the firm that wrote it.

Against the companies it is compared to

median P/E 28.2× of 4 peers
CompanyMarket capP/EEV/EBITDAGrossNetROE
MOAltria Group, Inc.$115B14.5×11.7×71.0%36.5%-265%
CLColgate-Palmolive Company$69B33.8×19.6×60.4%9.7%631%
MDLZMondelez International, Inc.$78B22.6×16.0×31.1%8.9%13%
MNSTMonster Beverage Corporation$86B40.3×28.1×55.5%23.1%25%
TGTTarget Corporation$71B16.1×9.9×29.3%4.1%27%

The median is of the 4 peers listed above and nothing else — check it against the column. This company trades 48.4% below it. The peer set is the vendor’s, so a company can appear here that a person would not have chosen.

What it has traded at

P/E by fiscal year
FY14 19.2×FY25 14.0×

What its sector has traded at

Consumer Defensive
FY14 22.9×FY26 39.1×

Two scales, drawn separately on purpose: a sector median and one company’s multiple are not the same number and putting them on one axis invites a comparison neither series supports.

Discounted cash flow

not recomputed since
ModelFair valueAgainstComputed
Standard DCF$107$73.16 · +46%2026-06-10
Levered DCF$92$73.16 · +26%2026-06-10

The vendor’s intrinsic-value models. Treat them as a low-growth anchor — for a fast grower the market routinely pays well above a DCF. These were computed against the price in the “against” column, not today’s.

Every estimate on one scale

price $69.77
52-week range$55 – $77
Analyst targets$58 – $79
Standard DCF$107 as of 2026-06-10, when it was $73.16
Levered DCF$92 as of 2026-06-10, when it was $73.16
At own 5y-median P/E (14×)$66
At 5y P/E range (8–35×)$38 – $167
At sector P/E (38×)$181

The vertical rule is the current price. Ranges and point estimates are the backend’s, published as they were calculated; an arrow means the estimate sits beyond this scale, and its number is on the right.